SK Life Science, Inc. (a Paramus, New Jersey-based biopharmaceutical enterprise and a subsidiary of South Korea’s SK Biopharmaceuticals Co., Ltd.) has officially announced that the U.S. Food and Drug Administration (FDA) has accepted for review its New Drug Application (NDA) evaluating an investigational oral suspension formulation of Cenobamate. Engineered as a patient-centered therapeutic solution, the alternative liquid formulation is targeted to treat focal (partial-onset) seizures in adult cohorts, creating a critical alternative administration pathway for epilepsy patients presenting with severe dysphagia or clinical difficulties swallowing conventional solid tablets.
The documented PDUFA regulatory review timelines, underlying epidemiological frameworks of epilepsy, and highly restrictive safety alerts feature:
-
PDUFA Regulatory Evaluation Frameworks and NDA Dossier Support:
-
Chronological Targets: The federal agency has formally assigned a Prescription Drug User Fee Act (PDUFA) target action date of January 31, 2027, to conclude its clinical assessment. The operational acceptance of the filing confirms that the regulatory package satisfies baseline structural requirements to initiate formal scientific evaluation, rather than constituting an active marketing authorization at this stage of the pipeline.
-
Supporting Clinical Metrics: The comprehensive regulatory submission packages detailed data packages validating the safety, biological tolerability, and pharmacokinetic profiles established by the investigational liquid oral suspension formulation.
-
-
Epilepsy Disease Burdens and Unique Molecular Mechanisms of Action:
-
Epidemiological Footprint: Epilepsy operates as a chronic neurological condition characterized by recurrent, unprovoked seizures, tracking as the fourth most common neurological pathology globally. Within the United States, approximately 3.4 million individuals live with the disorder, with roughly 150,000 new cases identified annually. Crucially, nearly 40% of the active patient population fails to achieve definitive seizure freedom despite undergoing multi-drug antiepileptic regimens.
-
Molecular Targeted Kinetics: Cenobamate was discovered and synthesized through the joint R&D pipelines of SK Biopharmaceuticals and SK Life Science. The molecule dampens pathological neuronal hyperexcitability through a unique dual mechanism of action: preferentially blocking the persistent sodium current while simultaneously enhancing GABAergic inhibition via positive allosteric modulation at the type A γ-aminobutyric acid (GABAA) ion channel complex. In the U.S., the solid tablet formulation is commercialized under the brand name XCOPRI for adults aged 18 and older, and is distributed across the European Union, United Kingdom, and Switzerland under the trade name ONTOZRY.
-
-
Systemic Contraindications and Severe Clinical Risk Parameters:
-
Absolute Exclusions: The compound is strictly contraindicated in individuals presenting with documented hypersensitivity to cenobamate or any foundational excipient, as well as in patients diagnosed with Familial Short QT syndrome, a genetic cardiac channelopathy affecting the electrical conduction system of the heart.
-
Severe Systemic Adverse Reactions: The clinical registry highlights that cenobamate exposure can precipitate life-threatening systemic hypersensitivity reactions, including severe drug rashes affecting visceral organs (inducing hepatotoxicity or hematological cell dyscrasias). Furthermore, the drug can cause significant central nervous system impairments (acute dizziness, somnolence, ataxia, and cognitive slowing), carries an elevated suicide risk profile (manifesting suicidal ideation or behavior in approximately 1 in 500 patients), and can structurally degrade the pharmacological efficacy of hormonal contraceptives.
-
Federal Control Standings: Classified as a federally controlled substance under Schedule V (CV) due to its underlying potential for abuse or physiological dependence, the drug carries a strict black-letter warning against abrupt cessation. Sudden discontinuation of anti-seizure medication can instantly trigger status epilepticus—a continuous, unremitting seizure state constituting an absolute medical emergency.
-